Swiss medical technology company Ava has raised $30m in a strategic Series B funding round led by European VC firm btov, to advance its fertility tracking sensor bracelet for women.
The financing round was joined by Credit Suisse’s investment vehicle SVC and Ava’s existing investors.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Ava designed its sensor bracelet to accurately identify the 5.3-day fertile window in a woman’s cycle in real-time. The company plans to use the new funds to drive research and development for advancing the cycle-tracking device.
In addition, Ava intends to devise new applications targeting the reproductive health of women through data insights and science.
Ava co-founder Pascal Koenig said: “Ava’s long-term vision is to accompany women through all stages of their reproductive life by providing data-driven, clinically proven technology that will make a woman’s life easier, healthier and better — be it when they just want to understand their body, while they are trying to prevent pregnancy, trying to get pregnant, are pregnant or entering menopause.”
The company is currently performing various clinical trials to evaluate its technology at the University Hospital of Zurich led by professor Brigitte Leeners.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThese studies aim to help women who are trying to get pregnant or having fertility challenges. Ava also wants to gain better insights into complications that occur during pregnancy.
Leeners said: “Combining the best in science, data insights and technology is not only helping to create families but improving women’s lives around the world.”
